Phages are particularly advantageous anti-infectives as they are novel therapeutics, can target antibiotic-resistant bacteria ...

Molnupiravir is a pill used to treat COVID-19 in people who are at high risk of developing severe illness. It works by interfering with the ability of SARS‑CoV‑2 (the virus that causes COVID-19) to ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...

This is due to research showing that many cough remedies don't provide much more relief than a placebo, reports the Express.

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...

Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS ...

Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is presenting three posters highlighting pivotal new data ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...